Akero Therapeutics Announces Closing of Public Offering of Common Stock
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
Akero Bounces Back in MASH, Posts Positive Mid-Stage Fibrosis Data
Akero Therapeutics Reports Improvements at Week 96 in Phase 2b HARMONY Study
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Akero Reports Fourth Quarter and Full Year 2023 Financial Results
Akero to Present Topline Week 96 Results from Phase 2b HARMONY Study
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to...